CN111665359A - 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 - Google Patents
一种肺癌的外周血tcr标志物及其检测试剂盒和应用 Download PDFInfo
- Publication number
- CN111665359A CN111665359A CN202010665298.3A CN202010665298A CN111665359A CN 111665359 A CN111665359 A CN 111665359A CN 202010665298 A CN202010665298 A CN 202010665298A CN 111665359 A CN111665359 A CN 111665359A
- Authority
- CN
- China
- Prior art keywords
- artificial sequence
- lung cancer
- ser
- ala
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 130
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 130
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 130
- 239000003550 marker Substances 0.000 title claims abstract description 33
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 16
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 11
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 238000007405 data analysis Methods 0.000 abstract 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 56
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 33
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 108091008875 B cell receptors Proteins 0.000 description 9
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 8
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- QOCFFCUFZGDHTP-NUMRIWBASA-N Asp-Thr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOCFFCUFZGDHTP-NUMRIWBASA-N 0.000 description 6
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- QYXNFROWLZPWPC-FXQIFTODSA-N Asn-Glu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QYXNFROWLZPWPC-FXQIFTODSA-N 0.000 description 5
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108010010147 glycylglutamine Proteins 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- PBYFVIQRFLNQCO-GUBZILKMSA-N Gln-Pro-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O PBYFVIQRFLNQCO-GUBZILKMSA-N 0.000 description 4
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 4
- 208000002151 Pleural effusion Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- WAPFQMXRSDEGOE-IHRRRGAJSA-N Tyr-Glu-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O WAPFQMXRSDEGOE-IHRRRGAJSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 3
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 3
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 3
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010170 biological method Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010087823 glycyltyrosine Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 2
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 2
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 2
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 2
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 2
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 2
- MWTGQXBHVRTCOR-GLLZPBPUSA-N Glu-Thr-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MWTGQXBHVRTCOR-GLLZPBPUSA-N 0.000 description 2
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 2
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 2
- 108010066302 Keratin-19 Proteins 0.000 description 2
- 102000018317 Keratin-19 Human genes 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 2
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 2
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 2
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 2
- MFMGPEKYBXFIRF-SUSMZKCASA-N Thr-Thr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFMGPEKYBXFIRF-SUSMZKCASA-N 0.000 description 2
- NMKJPMCEKQHRPD-IRXDYDNUSA-N Tyr-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NMKJPMCEKQHRPD-IRXDYDNUSA-N 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 2
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000011493 immune profiling Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108010071207 serylmethionine Proteins 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 1
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- CYBJZLQSUJEMAS-LFSVMHDDSA-N Ala-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)N)O CYBJZLQSUJEMAS-LFSVMHDDSA-N 0.000 description 1
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- OMCKWYSDUQBYCN-FXQIFTODSA-N Ala-Ser-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O OMCKWYSDUQBYCN-FXQIFTODSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 1
- AOAKQKVICDWCLB-UWJYBYFXSA-N Ala-Tyr-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AOAKQKVICDWCLB-UWJYBYFXSA-N 0.000 description 1
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 1
- IJPNNYWHXGADJG-GUBZILKMSA-N Arg-Ala-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O IJPNNYWHXGADJG-GUBZILKMSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 1
- JAYIQMNQDMOBFY-KKUMJFAQSA-N Arg-Glu-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JAYIQMNQDMOBFY-KKUMJFAQSA-N 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- NKNILFJYKKHBKE-WPRPVWTQSA-N Arg-Gly-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NKNILFJYKKHBKE-WPRPVWTQSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- INXWADWANGLMPJ-JYJNAYRXSA-N Arg-Phe-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CC1=CC=CC=C1 INXWADWANGLMPJ-JYJNAYRXSA-N 0.000 description 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 1
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 1
- FMYQECOAIFGQGU-CYDGBPFRSA-N Arg-Val-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FMYQECOAIFGQGU-CYDGBPFRSA-N 0.000 description 1
- FUHFYEKSGWOWGZ-XHNCKOQMSA-N Asn-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O FUHFYEKSGWOWGZ-XHNCKOQMSA-N 0.000 description 1
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 1
- PHJPKNUWWHRAOC-PEFMBERDSA-N Asn-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PHJPKNUWWHRAOC-PEFMBERDSA-N 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 1
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 1
- FMNBYVSGRCXWEK-FOHZUACHSA-N Asn-Thr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O FMNBYVSGRCXWEK-FOHZUACHSA-N 0.000 description 1
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 1
- SOYOSFXLXYZNRG-CIUDSAMLSA-N Asp-Arg-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O SOYOSFXLXYZNRG-CIUDSAMLSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 1
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 1
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 description 1
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 1
- KESWRFKUZRUTAH-FXQIFTODSA-N Asp-Pro-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O KESWRFKUZRUTAH-FXQIFTODSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- AWPWHMVCSISSQK-QWRGUYRKSA-N Asp-Tyr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O AWPWHMVCSISSQK-QWRGUYRKSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 1
- PHZYLYASFWHLHJ-FXQIFTODSA-N Gln-Asn-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PHZYLYASFWHLHJ-FXQIFTODSA-N 0.000 description 1
- JKPGHIQCHIIRMS-AVGNSLFASA-N Gln-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N JKPGHIQCHIIRMS-AVGNSLFASA-N 0.000 description 1
- DRDSQGHKTLSNEA-GLLZPBPUSA-N Gln-Glu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRDSQGHKTLSNEA-GLLZPBPUSA-N 0.000 description 1
- ORYMMTRPKVTGSJ-XVKPBYJWSA-N Gln-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O ORYMMTRPKVTGSJ-XVKPBYJWSA-N 0.000 description 1
- FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- MFHVAWMMKZBSRQ-ACZMJKKPSA-N Gln-Ser-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N MFHVAWMMKZBSRQ-ACZMJKKPSA-N 0.000 description 1
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
- SOEXCCGNHQBFPV-DLOVCJGASA-N Gln-Val-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SOEXCCGNHQBFPV-DLOVCJGASA-N 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 1
- ZJICFHQSPWFBKP-AVGNSLFASA-N Glu-Asn-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZJICFHQSPWFBKP-AVGNSLFASA-N 0.000 description 1
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 1
- JRCUFCXYZLPSDZ-ACZMJKKPSA-N Glu-Asp-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O JRCUFCXYZLPSDZ-ACZMJKKPSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- WRNAXCVRSBBKGS-BQBZGAKWSA-N Glu-Gly-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O WRNAXCVRSBBKGS-BQBZGAKWSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 1
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 1
- SYAYROHMAIHWFB-KBIXCLLPSA-N Glu-Ser-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYAYROHMAIHWFB-KBIXCLLPSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- UCZXXMREFIETQW-AVGNSLFASA-N Glu-Tyr-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O UCZXXMREFIETQW-AVGNSLFASA-N 0.000 description 1
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 description 1
- MXXXVOYFNVJHMA-IUCAKERBSA-N Gly-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN MXXXVOYFNVJHMA-IUCAKERBSA-N 0.000 description 1
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 1
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- UPADCCSMVOQAGF-LBPRGKRZSA-N Gly-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)CN)C(O)=O)=CNC2=C1 UPADCCSMVOQAGF-LBPRGKRZSA-N 0.000 description 1
- SXJHOPPTOJACOA-QXEWZRGKSA-N Gly-Ile-Arg Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SXJHOPPTOJACOA-QXEWZRGKSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- JPAACTMBBBGAAR-HOTGVXAUSA-N Gly-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)CC(C)C)C(O)=O)=CNC2=C1 JPAACTMBBBGAAR-HOTGVXAUSA-N 0.000 description 1
- BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 1
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 1
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 1
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- FKQPWMZLIIATBA-AJNGGQMLSA-N Leu-Lys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FKQPWMZLIIATBA-AJNGGQMLSA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- WGLAORUKDGRINI-WDCWCFNPSA-N Lys-Glu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGLAORUKDGRINI-WDCWCFNPSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
- QBHGXFQJFPWJIH-XUXIUFHCSA-N Lys-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN QBHGXFQJFPWJIH-XUXIUFHCSA-N 0.000 description 1
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- HDNOQCZWJGGHSS-VEVYYDQMSA-N Met-Asn-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HDNOQCZWJGGHSS-VEVYYDQMSA-N 0.000 description 1
- YCUSPBPZVJDMII-YUMQZZPRSA-N Met-Gly-Glu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O YCUSPBPZVJDMII-YUMQZZPRSA-N 0.000 description 1
- VSJAPSMRFYUOKS-IUCAKERBSA-N Met-Pro-Gly Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O VSJAPSMRFYUOKS-IUCAKERBSA-N 0.000 description 1
- JHVNNUIQXOGAHI-KJEVXHAQSA-N Met-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N)O JHVNNUIQXOGAHI-KJEVXHAQSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 1
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 1
- KAJLHCWRWDSROH-BZSNNMDCSA-N Phe-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 KAJLHCWRWDSROH-BZSNNMDCSA-N 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- GTMSCDVFQLNEOY-BZSNNMDCSA-N Phe-Tyr-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N GTMSCDVFQLNEOY-BZSNNMDCSA-N 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- CMOIIANLNNYUTP-SRVKXCTJSA-N Pro-Gln-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O CMOIIANLNNYUTP-SRVKXCTJSA-N 0.000 description 1
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- FYPGHGXAOZTOBO-IHRRRGAJSA-N Pro-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FYPGHGXAOZTOBO-IHRRRGAJSA-N 0.000 description 1
- CPRLKHJUFAXVTD-ULQDDVLXSA-N Pro-Leu-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CPRLKHJUFAXVTD-ULQDDVLXSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- ANESFYPBAJPYNJ-SDDRHHMPSA-N Pro-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ANESFYPBAJPYNJ-SDDRHHMPSA-N 0.000 description 1
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- MMGJPDWSIOAGTH-ACZMJKKPSA-N Ser-Ala-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MMGJPDWSIOAGTH-ACZMJKKPSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- ICHZYBVODUVUKN-SRVKXCTJSA-N Ser-Asn-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ICHZYBVODUVUKN-SRVKXCTJSA-N 0.000 description 1
- CNIIKZQXBBQHCX-FXQIFTODSA-N Ser-Asp-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O CNIIKZQXBBQHCX-FXQIFTODSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 1
- VEVYMLNYMULSMS-AVGNSLFASA-N Ser-Tyr-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEVYMLNYMULSMS-AVGNSLFASA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- LSHUNRICNSEEAN-BPUTZDHNSA-N Ser-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CO)N LSHUNRICNSEEAN-BPUTZDHNSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- LHUBVKCLOVALIA-HJGDQZAQSA-N Thr-Arg-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LHUBVKCLOVALIA-HJGDQZAQSA-N 0.000 description 1
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- REJRKTOJTCPDPO-IRIUXVKKSA-N Thr-Tyr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O REJRKTOJTCPDPO-IRIUXVKKSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 description 1
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 1
- UJRIVCPPPMYCNA-HOCLYGCPSA-N Trp-Leu-Gly Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N UJRIVCPPPMYCNA-HOCLYGCPSA-N 0.000 description 1
- BIBZRFIKOLGWFQ-XIRDDKMYSA-N Trp-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O BIBZRFIKOLGWFQ-XIRDDKMYSA-N 0.000 description 1
- UJGDFQRPYGJBEH-AAEUAGOBSA-N Trp-Ser-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N UJGDFQRPYGJBEH-AAEUAGOBSA-N 0.000 description 1
- BOBZBMOTRORUPT-XIRDDKMYSA-N Trp-Ser-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 BOBZBMOTRORUPT-XIRDDKMYSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- GFHYISDTIWZUSU-QWRGUYRKSA-N Tyr-Asn-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O GFHYISDTIWZUSU-QWRGUYRKSA-N 0.000 description 1
- JRXKIVGWMMIIOF-YDHLFZDLSA-N Tyr-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JRXKIVGWMMIIOF-YDHLFZDLSA-N 0.000 description 1
- CKHQKYHIZCRTAP-SOUVJXGZSA-N Tyr-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O CKHQKYHIZCRTAP-SOUVJXGZSA-N 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- WSFXJLFSJSXGMQ-MGHWNKPDSA-N Tyr-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WSFXJLFSJSXGMQ-MGHWNKPDSA-N 0.000 description 1
- JLKVWTICWVWGSK-JYJNAYRXSA-N Tyr-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JLKVWTICWVWGSK-JYJNAYRXSA-N 0.000 description 1
- PYJKETPLFITNKS-IHRRRGAJSA-N Tyr-Pro-Asn Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O PYJKETPLFITNKS-IHRRRGAJSA-N 0.000 description 1
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- DJEVQCWNMQOABE-RCOVLWMOSA-N Val-Gly-Asp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)O)N DJEVQCWNMQOABE-RCOVLWMOSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002597 diffusion-weighted imaging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种肺癌的外周血TCR标志物及其检测试剂盒和应用,该标志物包括序列SpecSeq1‑100所示蛋白中的至少一种。本发明基于高通量测序方法,只需要采取少量外周血,提取RNA,通过对样本的处理建立免疫图谱文库,再经过高通量测序和TCR数据分析,首先确定肺癌外周血中特征性TCR序列,然后将待测样本测试结果与该特征性TCR序列比对,从而确定是否患有肺癌。本发明能够同时比较巨大数量的肺癌特异性TCR序列,相比单独检测一种或几种标记物,具有更高的特异性和准确性,提高了诊断效率。
Description
技术领域
本发明属于基因工程技术领域,尤其涉及一种肺癌的外周血TCR标志物及其检测试剂盒和应用。
背景技术
据世界卫生组织2018年最新统计数据显示,肺癌是全球最常见的恶性肿瘤,在各类癌症发病占比排名第一(11.6%,与女性乳腺癌并列),癌症死亡占比中排名也是第一(18.4%)。东亚是男性肺癌发病率最高的地区之一,在中国肺癌的发病率约为40/10万人,高于世界平均水平(31.5/10万人)。在中国,肺癌是男性发病占比最高的恶性肿瘤,也是死亡占比最高的恶性肿瘤(男女均是)。现有的肺癌治疗手段虽多,但病人的实际获益十分有限。早诊断、早治疗,是提高肺癌治疗效果,改善患者预后,节约社会资源的迫切需求。
目前针对肺癌的诊断手段主要分为生物化学方法、分子生物学方法、细胞学方法和影像学方法四大类。
1、生物化学方法
通过酶联免疫检测(ELISA)等方法,检查患者组织样本(血液、血清、胸腔积液等)中的肿瘤标志物。常见生物化学检测肿瘤标志物有:
癌胚抗原(CEA):CEA是表达于胎儿上皮细胞的一种糖蛋白,分子量为180kD。在成人结肠的正常黏膜上皮和其他组织当中有极低的表达,在胃肠道腺癌、肺腺癌和甲状腺髓样癌当中高表达,其主要是用于检测上皮性肿瘤,尤其是来源于腺上皮的腺癌。CEA水平在肺癌腺癌中的升高是最为明显的,表明CEA在鉴别肺部的良、恶性肿瘤及其组织学分型中具有重要的作用。CEA可以作为肺癌患者胸腔积液检测的肿瘤标志物。
鳞状细胞癌抗原(Squamous Cell Carcinoma Antigen,SCCA)是丝氨酸蛋白酶抑制剂家族的一员,在肺癌患者组织和血清中SCCA过度表达,可能是诊断肺癌更加有希望的生物标志物。
常用于肺癌诊断的分子标记物还有糖类抗原(Carbohydrate Antigen,包括CA19-9、CA12-5、CA50、CA15-3等)、细胞角蛋白19片段抗原21-1(Cytokeratin19 FragmentAntigen21-1,CYFRA21-1)、人多效蛋白(Pleiotrophin,PTN)、神经元特异性烯醇化酶(Neuron-Specific Enolase,NSE)等,但检测单个抗原对肺癌诊断的特异度较低,多个抗原抗体的组合检测可能会提高肺癌的诊断效率。
生物化学方法的肺癌肿瘤标志物,往往难以在灵敏度和特异性两方面都令人满意,应用于肺癌诊断时,必须综合评估多种标志物。这必然提高检测成本,并且多种指标的综合评估,对最终检测结果的判读造成了困难。
2、分子生物学方法
通过基因测序的方法,检查患者组织样本(血液、血清、活检标本)中的肿瘤标志物。常见的分子生物学肿瘤标志物有:
EGFR基因:EGFR在大多数非小细胞肺癌(NSCLC)中过表达且是重要的治疗靶标。目前已知大部分的NSCLC均存在EGFR过表达,其中鳞癌的表达率约为85%,腺癌和大细胞癌的表达率约为65%,而小细胞癌的表达率较低。
KRAS基因:KRAS与肺癌的发生以及预后有关。有20%~30%的NSCLC患者存在着KRAS的基因突变。
甲状腺转录因子1(TTF-1):TTF-1是一种分子量为38~40KD的核蛋白,在胎儿的肺组织和成人Ⅱ型肺泡上皮细胞中存在,但在Ⅰ型肺泡上皮细胞中不表达。TTF-1的阳性表达是肺腺癌特异的免疫组化诊断标志物,有助于转移性腺癌和原发性腺癌的鉴别。
神经细胞黏附分子(N-CAM/CD56)等,其中,CD56是诊断小细胞癌的特异性标记物,其在90%SCLC细胞膜强阳性。而早期标志物监测中单克隆抗体对肺癌诊断效果中,诊断敏感性和特异性分别为:92.00%、89.00%。
P53是一个重要的抗癌基因,其与细胞周期的调控、修复、细胞分化、细胞凋亡等生物学功能有关,功能异常可导致细胞生长异常。肺癌患者最常见为P53突变,P53通过影响beta-catenin信号通路发挥对EMT的调控作用,降低P53表达能够促进betacatenin的细胞核内积累及转录活性,抑制beta-catenin信号通路可减弱P53降低所促进的肺癌细胞EMT、细胞迁移和肿瘤转移,其P53突变预示较差的预后。
综上所述,分子生物学方法的肺癌肿瘤标志物,也存在难以在灵敏度和特异性两方面都令人满意的问题。应用于肺癌诊断时,必须综合评估多种标志物。这必然提高检测成本,并且多种指标的综合评估,对最终检测结果的判读造成了困难。
3、细胞学方法
对病人痰液、支气管分泌物、胸腔积液进行脱落细胞检测,但存在一些问题:对肿瘤检测的特异性较高,但灵敏度不理想;检测出癌细胞,也无法对肿瘤进行定位;为保证可靠性,检测需要的工作量大;抽取胸腔积液对病人的痛苦和伤害较大等等。
4、影像学方法
1)X线计算机断层成像(Computed Tomography,CT),其检出和诊断能力总体略逊于磁共振成像。目前除常见应用于肺癌临床诊断及分期外,更多应用于肺癌局部治疗的疗效评价。但CT存在辐射伤害较大,且难以发现≤1CM肿瘤等缺点。
2)核医学影像检查,如正电子发射计算机断层成像(Positron EmissionTomography/CT,PET/CT),优势在于:对肿瘤进行分期,通过一次检查能够全面评价淋巴结转移及远处器官的转移;再分期,因PET功能影像不受解剖结构的影响,可准确显示解剖结构发生变化后或者是解剖结构复杂部位的复发转移灶;疗效评价,对于抑制肿瘤活性的靶向药物,疗效评价更加敏感、准确;指导放疗生物靶区的勾画、穿刺活检部位;评价肿瘤的恶性程度和预后。缺点在于设备昂贵,检测费用高。
3)磁共振成像(Magnetic Resonance Imaging,MRI),具有无辐射影响,组织分辨率高,可以多方位、多序列参数成像,并具有形态结合功能(包括弥散加权成像、灌注加权成像和波谱分析)综合成像技术能力,成为临床肺癌检出、诊断和疗效评价的常用影像技术。但核磁共振检测存在设备昂贵体积巨大,占用空间大,检测费用高等缺点。
发明内容
本发明的目的在于:针对现有技术中存在的不足,提供一种肺癌的外周血TCR标志物及其检测试剂盒和应用。
本发明采用的技术方案如下:
一种肺癌的外周血TCR标志物,包括序列SpecSeq1-100所示蛋白中的至少一种,具体序列见表1:
表1标志物序列
进一步地,标志物的蛋白序列为SpecSeq1-100所示的序列经取代、缺失和/或替换一个或多个碱基后,能表达相同功能的蛋白。
上述的标志物在制备检测或治疗肺癌的制剂中的应用。
进一步地,制剂包括含有该标志物的T细胞受体的质粒、病毒载体或核酸片段。
一种用于肺癌检测的试剂盒,包括能与上述标志物发生特异性结合的抗体。
一种制剂,包括能与上述标志物发生特异性结合的抗体;制剂可用于对肺癌进行诊断、预测、检测或筛查。
一种检测肺癌的蛋白质芯片,蛋白质芯片包括基片和点样在基片上特异性抗体,特异性抗体为能与上述标志物发生特异性结合的抗体。
本发明的原理为:人体内的B淋巴细胞和T淋巴细胞是获得性免疫系统中重要的两类细胞。B细胞通过细胞表面的B细胞受体(BCR)识别抗原,后期BCR在B细胞分化成浆细胞时,表达成抗体,分泌到细胞外。T细胞通过细胞表面的T细胞受体(TCR)识别抗原。BCR和TCR的多样性是建立获得性免疫系统的基础。BCR多样性的理论值是1018,TCR多样性的理论值是1014。BCR与TCR序列中,抗原决定簇3(CDR3)是决定其抗原特异性最重要的部分,因此CDR3的序列被认为可以代表BCR、TCR序列的特性。
在各种疾病中,随着不同的抗原刺激,BCR和TCR的多样性或者表达水平都会发生改变。因此,利用BCR或者TCR高通量测序结果可以追踪疾病的发生、发展。人体内细胞中,衰老蛋白质降解后,其片段会被运输到细胞表面,通过组织相容性抗原II(MCHII)呈递给免疫系统中的T细胞。正常细胞呈递的抗原片段,由于免疫耐受的关系,不会引起免疫反应。一旦当正常细胞出现癌变后,突变的基因表达的异常蛋白,其片段被呈递到细胞表面后,就会引起人体免疫系统产生针对性的免疫反应。因此,分析BCR或TCR的变化,能够检测出肿瘤的发生和发展。
本发明应用时,采用基于高通量测序分析外周血TCR序列方法以检测是否患有肺癌,具体步骤如下:
(1)采集受试者和对照组外周血,通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于30000;
(2)对每个样本的TCR的CDR3序列进行随机不放回抽样,使每个样本的CDR3序列数量总和均为30000;对任一特定CDR3序列X,在该样本中重复出现次数计为CX;
(3)TCR CDR3数据分析:通过分析确定肺癌TCR标志物CDR3序列:
a)将对照组样本所有CDR3序列归总、去重,设为对照序列集;
b)将肺癌样本所有CDR3序列归总、去重,再去除所有与对照序列集中包含CDR3序列重复的序列,设为肺癌特征序列集;
c)将肺癌特征序列集中,出现于两个及以上样本中的CDR3序列,按“在所有肺癌样本中该序列重复出现次数CX的总和×包含该序列的肺癌样本数”从高到低排序,以筛选出肺癌TCR标志物CDR3序列。
(4)利用肺癌特征性指数判断未知受试者罹患肺癌风险:
a)根据健康对照组、非肿瘤病人、非肺癌肿瘤患者、肺癌患者以及未知健康状况受试者的免疫图谱,分析其肺癌特征性指数;
其中肺癌特征性指数定义为:某个样本中,属于肺癌特征序列集的所有CDR3序列在该样本内重复出现次数CX的总和;
b)当未知健康状况受试者的肺癌特征性指数高于或接近“其它肿瘤”组的平均值+2×SD时,此人具有较高风险罹患肺癌;如其肺癌特征指数接近健康人或非肿瘤疾病组平均值,则表明其患肺癌风险低。
综上所述,由于采用了上述技术方案,本发明的有益效果是:
1、本发明中,首先利用非肺癌的对照组样本和肺癌病人的TCR高通量测序数据建立了人工智能分析模型,通过和这些肺癌特异性TCR序列对比,可以清楚的判断待测样本中是否有较高肺癌风险者;
2、通过高通量测序分析TCR变化可以发现很早期的肺癌,利用肺癌特有的TCRCDR3序列分析人的免疫系统中的T细胞对肺癌的反应,是一种新型的检测方法;
3、本发明中,由于采用高通量测序技术,同时比较巨大数量的特异性TCR序列,比起单独检测一种或几种标记物,具有更高的特异性和准确性;
4、本发明中使用的高通量测序仪器成本低于大型影像学设备,且可向第三方外包,此外,采样、处理的人力成本低于同时检测多种标记物,也低于大量细胞学检测,因此,本发明大大降低了检测成本;
5、本发明只需要采取少量外周血,采样简便、安全;
6、本发明中所述TCR CDR3序列,也可用于肺癌的免疫治疗。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1为本发明中,对照组CDR3序列及肺癌特征序列。横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或肺癌特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值;肺癌患者的免疫图谱具有多个种类且重复次数较高的肺癌特征序列,健康人极少肺癌特征序列,而未知受试者的肺癌特征比较明显,说明罹患肺癌风险较高。
图2为本发明中,针对肺癌特征序列集,计算健康人、非肿瘤病人、非肺癌肿瘤患者和肺癌患者的肺癌特征性指数,健康人、非肿瘤病人、非肺癌肿瘤患者的肺癌特征性指数均与肺癌患者具有显著差异,证明了肺癌特征序列集的特异性。据此可以判断未知受试者是否罹患肺癌。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明,即所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。因此,以下对在附图中提供的本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明的实施例,本领域技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
通过免疫图谱分析,获得肺癌TCR标志物CDR3序列集:
1、采样及免疫图谱分析
采集1301名对照组(包括健康人和非肿瘤疾病病人,1300人用于建立模型,1个健康人用于验证)、41名肺癌患者(40人用于建立模型,1人用于验证)及1名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于30000;
2、对每个样本的TCR的CDR3序列进行随机不放回抽样,使每个样本的CDR3序列数量总和均为30000。对任一特定CDR3序列X,在单样本测序结果中重复出现次数计为CX;
3、通过分析TCR CDR3数据,确定肺癌TCR标志物CDR3序列:
a)将1300名用于建立模型的对照组样本的所有CDR3序列归总去重,设为对照序列集;
b)将40名用于建立模型的肺癌样本的所有CDR3序列归总去重,再去除所有与对照序列集中包含序列重复的序列,设为肺癌特征序列集。如图1A所示,其中横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或肺癌特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值。
c)按照同样作图方法,将1名健康人、1名肺癌患者和1名健康状况未知受试者的免疫图谱,参照对照序列集合和肺癌特征序列集合进行作图,如图1B-D。从图中可见,肺癌患者的免疫图谱中,含有较多种类且较高重复出现次数的肺癌特征序列;健康人的免疫图谱中,只有极少量肺癌特征序列;而未知健康状况受试者,有高于健康人的肺癌特征序列,说明此人有较高风险罹患肺癌。
d)将肺癌特征序列集中,将所有出现在两个及以上参与建模肺癌样本里的CDR3序列,按“所有参与建模肺癌样本里该序列单样本中重复出现次数CX的总和×包含该序列的参与建模肺癌样本数”从高到低排序,排名前100者即为肺癌TCR标志物CDR3序列,具体序列如SpecSeq1~100所示。
实施例2
验证肺癌TCR标志物CDR3序列集的特异性:
1、采样及免疫图谱分析
采集304名非肺癌的肿瘤患者、6名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于30000;对每个样本的TCR的CDR3序列进行随机不放回抽样,使每个样本的CDR3序列数量总和均为30000。
2、从实施例1的对照组中随机挑选100名健康人及45名非肿瘤疾病病人。
3、根据来自实施例1的100名健康人、45名非肿瘤疾病病人、40名肺癌患者,以及实施例2新获取的304名非肺癌肿瘤患者、6名未知健康状况受试者的免疫图谱,分析其肺癌特征性指数。
其中肺癌特征性指数定义为:某个样本中,属于肺癌特征序列集的所有CDR3序列在该样本内重复出现次数CX的总和。
分析结果见下表2及图2。肺癌组与健康人(p=1.9E-78)、非肿瘤疾病(p=6.6E-43)、其它肿瘤(p=9.9E-162)都有显著差异,这证明了肺癌特征序列集的特异性。
表2不同样本组的肺癌特征性指数
4、分析各组的肺癌特征指数(下表3),未知健康状况受试者(检测样本)中,前4人的肺癌特征指数高于或接近“其它肿瘤”组的平均值+2×SD(347+2×1048=2443),此4人具有较高风险罹患肺癌;后2人肺癌特征指数接近健康人或非肿瘤疾病组平均值,罹患肺癌风险低。与临床体检结果对照后,前4人确为肺癌患者,而后2人为健康人。证明了利用肺癌特征序列集及肺癌特征性指数,预测受试者罹患肺癌风险的可行性。
表3肺癌特征性指数分析表
健康人 | 非肿瘤疾病 | 其他肿瘤 | 肺癌 | 检测样本 | |
Mean | 51 | 48 | 347 | 12818 | 2755 |
SD | 22.26 | 27.60 | 1047.91 | 3170.85 | 2816.96 |
mean+2SD | 95.8652 | 103.501 | 2443.12 |
综上所述,本发明所述肺癌TCR标志物CDR3序列,确实具有显著的肺癌特异性,不仅可以用于肺癌预测受试者罹患肺癌风险,未来还可用于肺癌的生物免疫治疗。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
序列表
<110> 成都益安博生物技术有限公司
<120> 一种肺癌的外周血TCR标志物及其检测试剂盒和应用
<160> 100
<170> SIPOSequenceListing 1.0
<210> 1
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala Ser Ser Trp Leu Gly Gln Phe Asn Thr Glu Ala Phe
1 5 10
<210> 2
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ala Ser Ser Arg Phe Arg Asp Gly Arg Trp Pro Gln His
1 5 10
<210> 3
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ala Ser Ser Leu Ala Pro Asn Ser Tyr Tyr Gly Tyr Thr
1 5 10
<210> 4
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ala Ser Ala Ala Leu Gly Glu Gly Arg Tyr Glu Gln Tyr
1 5 10
<210> 5
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ala Thr Ser Arg Glu Tyr Thr Gly Thr Ser Thr Asp Thr Gln Tyr
1 5 10 15
<210> 6
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Ser Val Gln Ser Ser Gly Thr Gly Glu Gly Pro Leu His
1 5 10
<210> 7
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Ser Ser Ser Pro Thr Val Leu Asp Thr Gln Tyr
1 5 10
<210> 8
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Ala Ser Ser Leu Lys Pro Ser Gly Gly Asp Glu Gln Phe
1 5 10
<210> 9
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Ser Val Leu Pro Gly Gly Arg Glu Lys Leu Phe
1 5 10
<210> 10
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Ala Ser Ser Ile Ala Gly Asp Ser Ser Tyr Asn Glu Gln Phe
1 5 10
<210> 11
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Ala Ser Ser Gln Val Val Arg Pro Arg Lys Glu Thr Gln Tyr
1 5 10
<210> 12
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Ala Ile Ser Glu Ser Thr Ala Trp Ser Glu Glu Thr Gln Tyr
1 5 10
<210> 13
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Ala Ser Ser Ser Pro Gln Gly Ile Arg Asp Val Glu Gln Phe
1 5 10
<210> 14
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Ala Ser Ser Asp Pro Asp Ser Thr Ala Thr Asn Glu Lys Leu Phe
1 5 10 15
<210> 15
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Ala Ser Ser Tyr Pro Asn Pro Gly Glu Gly Glu Ala Phe
1 5 10
<210> 16
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Gln Gln Leu Lys Ala Arg Ala Gly Glu Arg Ala Val
1 5 10
<210> 17
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Ala Thr Gly Tyr Gln Pro Gln His
1 5
<210> 18
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Ala Ser Ser Leu Ala Leu Ala Gly Thr Thr Gln Glu Thr Gln Tyr
1 5 10 15
<210> 19
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Ser Ala Arg Glu Val Ala Glu Leu Leu Tyr Glu Gln Tyr
1 5 10
<210> 20
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 20
Ala Thr Ser Arg Thr Arg Leu Ala Gly Gly Lys Asn Glu Gln Phe
1 5 10 15
<210> 21
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 21
Ala Ser Ile Leu Thr Gly Ser Ser Asn Gln Pro Gln His
1 5 10
<210> 22
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 22
Ala Thr Ser Glu Lys Glu Ser Asn Tyr Gly Tyr Thr
1 5 10
<210> 23
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 23
Ala Ser Ser Leu Leu Gly Val Gly Asp Phe Tyr Asn Glu Gln Phe
1 5 10 15
<210> 24
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 24
Ala Ser Ser Tyr Ile Lys Gly Asn Glu Gln Phe
1 5 10
<210> 25
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 25
Ala Ser Ser Leu Ser Tyr Ser Ala Asp Asn Glu Gln Phe
1 5 10
<210> 26
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 26
Ala Thr Ser Arg Val Arg Gly Leu Gly Gln Pro Gln His
1 5 10
<210> 27
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 27
Ala Ser Ser Phe Glu Glu Gly Gly Thr Asp Thr Gln Tyr
1 5 10
<210> 28
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 28
Ala Ser Thr Ser Tyr Gln Gly Arg Met Thr Tyr Gly Tyr Thr
1 5 10
<210> 29
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 29
Ala Ser Ser Ser Ala Gln Gly Gly Lys Asn Ile Gln Tyr
1 5 10
<210> 30
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 30
Pro Ala Pro Pro Ser Gly Arg Gly Val Thr Ser Ser Thr
1 5 10
<210> 31
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 31
Ala Ser Ser Tyr Ser Thr Thr Ala Gly Glu Tyr
1 5 10
<210> 32
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 32
Ala Ser Ser Thr Ser Trp Thr Asn Thr Glu Ala Phe
1 5 10
<210> 33
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 33
Ala Ser Arg Pro Lys Pro Gly Gln Ala Phe Ser Gly Asn Thr Ile Tyr
1 5 10 15
<210> 34
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 34
Ala Ser Ser Leu Pro Gly Leu Leu Ala Glu Gln Tyr
1 5 10
<210> 35
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 35
Ala Ile Ser Glu Arg Leu Gly Pro Tyr Glu Gln Tyr
1 5 10
<210> 36
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 36
Gln Arg Arg Pro Arg Gly Gly Ala Leu Arg Ala Val
1 5 10
<210> 37
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 37
Ser Ala Pro Gly Leu Ala Gly Gly Phe Leu Tyr Thr Gln Tyr
1 5 10
<210> 38
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 38
Ala Ser Ser Arg Leu Gln Arg Arg Asn Gln Pro Gln His
1 5 10
<210> 39
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 39
Ala Ser Ser Phe Arg Ser Gly Arg His Thr Thr Gly Glu Leu Phe
1 5 10 15
<210> 40
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 40
Gln Gln Leu Asp Arg Leu Gly Leu Trp Leu His
1 5 10
<210> 41
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 41
Ala Thr Ser Leu Ala Gly Ala Pro Asp Thr Gln Tyr
1 5 10
<210> 42
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 42
Ser Ala Arg Gly Leu Ala Gly Lys Leu Ser Ser Tyr Asn Glu Gln Phe
1 5 10 15
<210> 43
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 43
Ala Ser Ser His Asp Gly Ala Ala Ser Thr Tyr Glu Gln Tyr
1 5 10
<210> 44
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 44
Ala Ser Ser Val Arg Gln Ser Ser Asn Thr Glu Ala Phe
1 5 10
<210> 45
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 45
Ala Thr Ser Asp Leu Gln Gly Asp Ser Asn Glu Gln Phe
1 5 10
<210> 46
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 46
Ala Thr Ser Arg Asp Thr Leu Ala Gly Ala Asp Gly Asp Thr Gln Tyr
1 5 10 15
<210> 47
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 47
Ala Ser Lys Met Gly Glu Asn Glu Gln Phe
1 5 10
<210> 48
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 48
Ser Ala Leu Gly Thr Glu Glu Asn Tyr Gly Tyr Thr
1 5 10
<210> 49
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 49
Ala Ser Ser Pro Arg Pro Leu Ala Gly Ala Glu Asp Thr Gln Tyr
1 5 10 15
<210> 50
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 50
Ala Ser Ser Thr Thr Gln Asp Ser Asp Thr Gln Tyr
1 5 10
<210> 51
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 51
Ala Ser Ser Glu Asp Leu Ser Asp Arg Ser Arg Glu Thr Gln Tyr
1 5 10 15
<210> 52
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 52
Ala Ser Ile Pro Gly Asn Ile Tyr Glu Gln Tyr
1 5 10
<210> 53
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 53
Ala Thr Ser Glu Gly Gln Gly Glu Glu Glu Gln Tyr
1 5 10
<210> 54
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 54
Ala Ser Ser Arg Gly Glu Gly Thr Gln Glu Thr Gln Tyr
1 5 10
<210> 55
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 55
Ala Ser Arg Ser Gly Thr Thr Pro Ser Tyr Glu Gln Tyr
1 5 10
<210> 56
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 56
Ser Ala Arg Gly Glu Asp Arg Val Ile Asp Tyr Gly Tyr Thr
1 5 10
<210> 57
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 57
Ser Val Ala Ser Asp Gly Arg Gly Arg Ala Phe
1 5 10
<210> 58
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 58
Ala Ser Ser Tyr Arg Arg Gly Gln Asn Glu Gln Phe
1 5 10
<210> 59
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 59
Ser Pro Ser Gly Gly Arg Gly Thr Asp Thr Gln Tyr
1 5 10
<210> 60
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 60
Ala Ser Ser Phe Gly Gln Arg Gly Ser Asn Thr Gly Glu Leu Phe
1 5 10 15
<210> 61
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 61
Ala Ser Ser Gly Thr Gly Met Asn Thr Asp Thr Gln Tyr
1 5 10
<210> 62
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 62
Ala Ser Thr Ser Arg Asn Glu Ala Phe
1 5
<210> 63
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 63
Ala Ser Ser Asp Lys Pro Ile Glu Ala Phe
1 5 10
<210> 64
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 64
Gln Gln Leu Gly Pro Ser Gly Asp Asp Pro Arg Asp Pro Val
1 5 10
<210> 65
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 65
Ala Ser Ser Pro Met Pro Ala Gly Leu Asn Glu Gln Phe
1 5 10
<210> 66
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 66
Ala Ser Ser Phe Phe Asp Ser Asn Ser Gly Ala Asn Val Leu Thr
1 5 10 15
<210> 67
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 67
Ala Ser Ser Leu Lys Thr Gly Thr Ile Tyr Gly Tyr Thr
1 5 10
<210> 68
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 68
Ala Ser Gly Lys Ser Gln Tyr Thr Glu Ala Phe
1 5 10
<210> 69
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 69
Ser Val Val Trp Ser Gly Pro Leu Tyr Gly Tyr Thr
1 5 10
<210> 70
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 70
Ala Ser Ser Glu Gly Gly Phe Pro Leu Asn Glu Gln Phe
1 5 10
<210> 71
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 71
Ala Thr Ser Asp Leu Val Lys Thr Asp Thr Gln Tyr
1 5 10
<210> 72
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 72
Ala Ser Ser Gln Asp Phe Ser Val Trp Asp Thr Gln Tyr
1 5 10
<210> 73
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 73
Ala Ser Met Arg Thr Ala Ala Tyr Asn Glu Gln Phe
1 5 10
<210> 74
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 74
Ser Val Leu Asn Leu Ala Asp Lys Asn Ile Gln Tyr
1 5 10
<210> 75
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 75
Ala Ser Ser Ile Ala Gly Asp Ser Ser Tyr Asn Gly Ala Val
1 5 10
<210> 76
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 76
Ala Ser Ser Met Pro Gly Thr Arg Gly Arg Arg Glu Gln Tyr
1 5 10
<210> 77
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 77
Ala Ser Ser Tyr Ser Ala Ser Thr Val Gly Glu Thr Gln Tyr
1 5 10
<210> 78
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 78
Ala Ser Ser Gln Leu Gly Gly Arg Val Thr Thr Asp Thr Gln Tyr
1 5 10 15
<210> 79
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 79
Ala Ser Arg Ser Gly Ser Met Tyr Thr Asp Thr Gln Tyr
1 5 10
<210> 80
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 80
Ala Ser Ser Thr Val Ala Gly Arg Gly Tyr Glu Gln Tyr
1 5 10
<210> 81
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 81
Ala Thr Ser Ser Val Ala Gly Glu Glu Gln Phe
1 5 10
<210> 82
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 82
Ala Ile Ser Glu Ser Asn Glu Ala Val Arg Asp Thr Gln Tyr
1 5 10
<210> 83
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 83
Ala Ser Ser Tyr Gly Gly Gln Met Asn Glu Gln Phe
1 5 10
<210> 84
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 84
Pro Ala Ala Trp Ser Leu Ala Gly Ala Val Gly Lys Arg Pro Ser Thr
1 5 10 15
<210> 85
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 85
Ala Ser Ser Leu Glu Ser Gly Gly Trp Asn Gly Tyr Thr
1 5 10
<210> 86
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 86
Ala Ser Ser Leu Lys Ile Arg Thr Phe Asn Gln Pro Gln His
1 5 10
<210> 87
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 87
Ala Ser Gly Arg Leu Phe Gly Thr Asp Thr Glu Ala Phe
1 5 10
<210> 88
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 88
Ala Ser Ser Leu Pro Gly Gln Ile Leu Tyr Glu Gln Tyr
1 5 10
<210> 89
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 89
Ala Ser Ser Lys Leu Gly Gln Gly Val Thr Glu Ala Phe
1 5 10
<210> 90
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 90
Ala Ser Ser Ala Gly Thr Leu Tyr Thr
1 5
<210> 91
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 91
Ala Ser Ser Thr Arg Gln Ala Ala Gln Asn Ser Asn Gln Pro Gln His
1 5 10 15
<210> 92
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 92
Ala Ser Ser Tyr Gly Pro Gly Trp Gly Asn Glu Gln Phe
1 5 10
<210> 93
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 93
Ala Ser Ser Glu Asp Ser Glu Tyr Asn Glu Gln Phe
1 5 10
<210> 94
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 94
Ser Val Glu Gly Ser Thr Ser Gly Gly Pro Ser Thr Asp Thr Gln Tyr
1 5 10 15
<210> 95
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 95
Ala Ser Ser Pro Ser Gly Ser Gly Tyr Gln Glu Thr Gln Tyr
1 5 10
<210> 96
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 96
Ala Ser Ser Gln Ser Cys Arg Ala Gln Pro Gln His
1 5 10
<210> 97
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 97
Ala Ser Ser Gln Thr Gly Glu Ser Ile Gln Tyr
1 5 10
<210> 98
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 98
Ala Ser Ser Tyr Lys Glu Gly Val Ser Pro Leu His
1 5 10
<210> 99
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 99
Ala Ser Ser Gly Arg Arg Tyr Asn Val Glu Gln Phe
1 5 10
<210> 100
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 100
Ala Ser Ser Ala Phe Thr Lys Ser Thr Asp Arg Gln Tyr
1 5 10
Claims (7)
1.一种肺癌的外周血TCR标志物,其特征在于,包括序列SpecSeq1-100所示蛋白中的至少一种。
2.根据权利要求1所述的肺癌的外周血TCR标志物,其特征在于,所述标志物的蛋白序列为SpecSeq1-100所示的序列经取代、缺失和/或替换一个或多个碱基后,能表达相同功能的蛋白。
3.权利要求1或2所述的标志物在制备检测或治疗肺癌的制剂中的应用。
4.根据权利要求3所述的应用,其特征在于,所述制剂包括含有该标志物的T细胞受体的质粒、病毒载体或核酸片段。
5.一种用于肺癌检测的试剂盒,其特征在于,包括能与权利要求1所述标志物发生特异性结合的抗体。
6.一种制剂,其特征在于,包括能与权利要求1所述标志物发生特异性结合的抗体。
7.一种检测肺癌的蛋白质芯片,其特征在于,所述蛋白质芯片包括基片和点样在基片上特异性抗体,所述特异性抗体为能与权利要求1所述标志物发生特异性结合的抗体。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010665298.3A CN111665359A (zh) | 2020-07-11 | 2020-07-11 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
PCT/CN2021/101540 WO2022012280A1 (zh) | 2020-07-11 | 2021-06-22 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010665298.3A CN111665359A (zh) | 2020-07-11 | 2020-07-11 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111665359A true CN111665359A (zh) | 2020-09-15 |
Family
ID=72392037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010665298.3A Pending CN111665359A (zh) | 2020-07-11 | 2020-07-11 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111665359A (zh) |
WO (1) | WO2022012280A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112321700A (zh) * | 2020-09-21 | 2021-02-05 | 四川省人民医院 | 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用 |
CN113030473A (zh) * | 2021-03-15 | 2021-06-25 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113567682A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
CN113563454A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种IgA肾病的外周血TCR标志物及其检测试剂盒和应用 |
WO2022012280A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
WO2022194036A1 (zh) * | 2021-03-15 | 2022-09-22 | 成都益安博生物技术有限公司 | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009009589A (es) * | 2007-03-05 | 2009-09-21 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
CN107488737B (zh) * | 2017-10-12 | 2020-06-19 | 中国医学科学院肿瘤医院 | 一种检测外周血tcr可变区编码基因的液体活检试剂盒及其应用 |
CN110627895B (zh) * | 2018-06-25 | 2021-03-23 | 北京大学 | 肺癌特异性tcr及其分析技术和应用 |
CN111665359A (zh) * | 2020-07-11 | 2020-09-15 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
-
2020
- 2020-07-11 CN CN202010665298.3A patent/CN111665359A/zh active Pending
-
2021
- 2021-06-22 WO PCT/CN2021/101540 patent/WO2022012280A1/zh active Application Filing
Non-Patent Citations (5)
Title |
---|
中国科协学会学术部: "《网络药理学-中药现代化的新思路与新方法》", 30 November 2014, 中国科学技术出版社, pages: 12 - 14 * |
王继贤 等: "《临床生化检验(第二版)》", 31 July 1996, 湖南科学技术出版社, pages: 260 - 261 * |
程书钧: "《癌前病变和癌前癌症》", 31 January 2017, 河南科学技术出版社, pages: 39 - 40 * |
胡智祥: "《医院临床检验技术操作规范与实(化)验室管理全书》", 31 August 2004, 银声音像出版社, pages: 110 - 113 * |
董吁钢 等: "《心血管疾病预防与康复》", 28 February 2013, 中山大学出版社, pages: 25 - 26 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022012280A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN112321700A (zh) * | 2020-09-21 | 2021-02-05 | 四川省人民医院 | 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用 |
CN113030473A (zh) * | 2021-03-15 | 2021-06-25 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
WO2022194039A1 (zh) * | 2021-03-15 | 2022-09-22 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
WO2022194036A1 (zh) * | 2021-03-15 | 2022-09-22 | 成都益安博生物技术有限公司 | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN113567682A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
CN113563454A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种IgA肾病的外周血TCR标志物及其检测试剂盒和应用 |
WO2023000688A1 (zh) * | 2021-07-23 | 2023-01-26 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
WO2023000689A1 (zh) * | 2021-07-23 | 2023-01-26 | 成都益安博生物技术有限公司 | 一种IgA肾病的外周血TCR标志物及其检测试剂盒和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2022012280A1 (zh) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111665359A (zh) | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 | |
CN111624339A (zh) | 一种肝癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012292A1 (zh) | 一种胰腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
CN110007083B (zh) | 作为转移性乳腺癌的生物标志物的透明质酸 | |
WO2022012284A1 (zh) | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012279A1 (zh) | 一种大肠癌的外周血tcr标志物序列及其检测试剂盒和应用 | |
CN111812325A (zh) | 一种乳腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
CN111624342A (zh) | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 | |
CN111679074A (zh) | 一种前列腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022194039A1 (zh) | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022194042A1 (zh) | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 | |
CN112345755A (zh) | 乳腺癌的生物标志物及其应用 | |
EP2525227B1 (en) | A method for detecting pancreatic cancer using the serological marker ULBP2 | |
CN102504027A (zh) | 一种多表位tk1抗体的制备及其在人群体检筛查中早期肿瘤检测和风险预警中的应用 | |
WO2022194033A1 (zh) | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022194036A1 (zh) | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 | |
CN113866413B (zh) | 一种结直肠癌诊断标志物及其应用 | |
CN109971853A (zh) | 一种与非小细胞肺癌诊断相关的分子标志物及其应用 | |
CN110846414A (zh) | 一种卵巢癌的预后诊断标志物组合及其应用 | |
WO2021045180A1 (ja) | 胃がんマーカー、及びこれを用いた検査方法 | |
KR20220014900A (ko) | 폐암 진단용 다중 바이오마커 및 이의 용도 | |
CN109266741A (zh) | 一种膀胱癌干细胞鉴定的试剂盒及其应用 | |
JP2021144052A (ja) | マーカー、ヒト精巣上体タンパク質4(he4)に基づく肺腺癌の再発を検出する方法および関連する使用 | |
Wu et al. | Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53-and phage-ELISA: Correlation to clinical parameters | |
Thornthwaite | Anti-malignin antibody in serum and other tumor marker determinations in breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |